Drug Type Small molecule drug |
Synonyms PF 5190457, PF-05190457, PF-5190457 |
Target |
Action inverse agonists |
Mechanism GHSR inverse agonists(Ghrelin/growth hormone secretagogue receptor inverse agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H32N6OS |
InChIKeyZIUDADZJCKGWKR-AREMUKBSSA-N |
CAS Registry1334782-79-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alcoholism | Phase 2 | - | - | |
| Diabetes Mellitus, Type 2 | Phase 1 | Belgium | 01 Dec 2010 |
Phase 2 | 42 | (PF-05190457) | dhbsqalkpk(lkhqqfdmwf) = ptnwcrpxkg hrhgwcjoku (vrarttsclh, 1.19) View more | - | 16 Mar 2022 | ||
placebo (Placebo) | dhbsqalkpk(lkhqqfdmwf) = qsgwyjanya hrhgwcjoku (vrarttsclh, 1.095) View more | ||||||
Phase 1 | - | 35 | wagfvelksx(vhtoyofjsj) = eefbqqhdqo pnquloqehf (wsuznnelqm, 7 - 35) View more | - | 01 Feb 2017 |





